
Senores Pharmaceuticals Limited has announced its financial results for the third quarter (Q3 FY25) ending December 31, 2024. The company posted robust growth in revenue and profitability, reflecting strong operational performance.
Key Financial Highlights (Q3 FY25 vs Q3 FY24):
- Revenue from Operations: ₹103.02 crore, a 31% YoY increase from ₹78.70 crore.
- Total Income: ₹108.17 crore, up 36% YoY from ₹79.50 crore.
- Profit Before Tax (PBT): ₹20.48 crore, a significant 99% increase from ₹10.26 crore in Q3 FY24.
- Net Profit (PAT): ₹16.43 crore, a stellar 131% YoY rise from ₹7.11 crore.
Nine-Month Financial Highlights (9M FY25 vs 9M FY24):
- Revenue from Operations: ₹284.04 crore, a 33% growth compared to ₹214.52 crore.
- Net Profit: ₹40.37 crore, a notable 19% YoY rise from ₹32.71 crore.
Operational Updates:
The company’s improved revenue figures were driven by a combination of efficient cost management, increased demand for its products, and strategic operational enhancements. Total expenses for the quarter rose to ₹87.69 crore compared to ₹69.25 crore in Q3 FY24, primarily due to higher material costs and employee benefit expenses.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.